US Broker Ratings

Merus N.V. (MRUS) Stock Analysis: Exploring a 62% Potential Upside in Innovative Oncology Solutions

Merus N.V. (NASDAQ: MRUS), a clinical-stage biotechnology company based in Utrecht, Netherlands, is capturing investor attention with its promising drug pipeline and significant potential upside, currently estimated at 62.17%. Operating..

Zai Lab Limited (ZLAB): Investor Outlook on a Biotech Powerhouse with 58.58% Upside Potential

Zai Lab Limited (NASDAQ: ZLAB), a prominent player in the biotechnology sector, has been making waves in the healthcare industry with its innovative approach to tackling critical medical conditions. Based..

PROCEPT BioRobotics (PRCT) Stock Analysis: Unveiling a 32% Potential Upside in the Healthcare Sector

PROCEPT BioRobotics Corporation (NASDAQ: PRCT), a player in the burgeoning medical devices industry, is gaining significant attention from investors due to its innovative advancements in surgical robotics. Specializing in urology,..

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: A 207% Upside Potential Awaits Investors

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) continues to capture the attention of investors with its promising pipeline and substantial growth potential. As a key player in the biotechnology industry, Ultragenyx focuses..

Viking Therapeutics, Inc. (VKTX) Investor Outlook: Assessing a Potential 185% Upside

Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company based in San Diego, California, is capturing the attention of investors with its promising portfolio and significant growth potential. Operating in the..

Arcellx, Inc. (ACLX) Stock Analysis: A Promising 58.94% Upside in the Biotech Sector

Arcellx, Inc. (NASDAQ: ACLX) has caught the attention of investors with significant potential upside in the biotechnology sector. Focused on developing innovative immunotherapies for cancer and other incurable diseases, Arcellx..

ICU Medical, Inc. (ICUI) Stock Analysis: Exploring a 42% Potential Upside with Strong Buy Ratings

ICU Medical, Inc. (NASDAQ: ICUI), a key player in the healthcare sector, is making waves in the medical instruments and supplies industry. With a market capitalization of $3.22 billion, this..

Krystal Biotech, Inc. (KRYS) Investor Outlook: Analyzing a 38.49% Upside Potential

Krystal Biotech, Inc. (NASDAQ: KRYS), a burgeoning player in the biotechnology sector, is capturing investor attention with a compelling upside potential of 38.49% based on current analyst ratings. With a..

TransMedics Group, Inc. (TMDX) Stock Analysis: A 20.8% Potential Upside with Innovative Organ Care Solutions

TransMedics Group, Inc. (NASDAQ: TMDX) emerges as a formidable player in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $3.8 billion, this U.S.-based company..

RadNet, Inc. (RDNT) Stock Analysis: A 29% Upside Potential with Strong Buy Ratings

RadNet, Inc. (NASDAQ: RDNT), a prominent player in the healthcare sector, is making waves in the diagnostics and research industry. With a market capitalization of $4.16 billion, RadNet is a..

Legend Biotech Corporation (LEGN) Stock Analysis: Exploring a 96% Potential Upside in Biotechnology

Legend Biotech Corporation (NASDAQ: LEGN) has emerged as a notable player in the biotechnology sector, captivating investor attention with its innovative approach to cancer treatment. Operating as a biopharmaceutical company,..

Oscar Health, Inc. (OSCR) Stock Analysis: Key Insights on a Healthcare Innovator with 21.65% Potential Upside

Oscar Health, Inc. (NYSE: OSCR) stands out as a dynamic player in the healthcare sector, specifically within the healthcare plans industry. With a market capitalization of $3.66 billion, the company..

Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Biotech with a 35.95% Potential Upside

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is capturing the attention of investors with its promising potential upside of 35.95%. As a clinical-stage biopharmaceutical company based in Redwood City, California, Soleno is..

Alkermes plc (ALKS) Stock Analysis: 35% Upside Potential and Strong Buy Ratings Boost Investor Outlook

Alkermes plc (ALKS), a prominent player in the healthcare sector, specializes in developing and commercializing pharmaceutical products tailored to address unmet medical needs. Headquartered in Dublin, Ireland, this biopharmaceutical company..

Repligen Corporation (RGEN) Stock Analysis: Strong Buy Ratings and 39% Potential Upside Draw Investor Attention

Repligen Corporation (NASDAQ: RGEN), a key player in the healthcare sector specializing in medical instruments and supplies, is capturing investor interest with its recent financial performance and market positioning. With..

Option Care Health, Inc. (OPCH): Investor Outlook on a Robust 29% Upside Potential

Option Care Health, Inc. (NASDAQ: OPCH) is capturing the attention of investors with a compelling growth story in the healthcare sector. As a leading provider of home and alternate site..

BrightSpring Health Services (BTSG) Investor Outlook: A 38% Upside Potential Beckons

BrightSpring Health Services, Inc. (BTSG), a key player in the healthcare sector specializing in Health Information Services, is attracting significant investor interest. With a robust market capitalization of $3.57 billion,..

Masimo Corporation (MASI) Stock Analysis: Exploring the 12.73% Upside Potential and Analyst Ratings

Masimo Corporation (NASDAQ: MASI), a key player in the healthcare industry, stands out in the medical devices sector due to its innovative patient monitoring technologies and automation solutions. Based in..

Akero Therapeutics, Inc. (AKRO) Investor Outlook: 48% Potential Upside in Biotech Stock

In the dynamic world of biotechnology, Akero Therapeutics, Inc. (NASDAQ: AKRO) stands out as an intriguing prospect for investors, driven by its focus on groundbreaking therapies for serious metabolic diseases...

Qiagen N.V. (QGEN) Stock Analysis: Steady Growth and a 4.16% Potential Upside

Qiagen N.V. (NASDAQ: QGEN), a leading player in the healthcare sector with a focus on diagnostics and research, presents an intriguing opportunity for investors seeking to capitalize on the expanding..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds